Get the Stockscreener App
19.95
0.15%
0.03
Pre-market:
19.94
-0.010
-0.05%
Adma Biologics Inc stock is traded at $19.95, with a volume of 1.66M.
It is up +0.15% in the last 24 hours and up +4.40% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$19.92
Open:
$19.87
24h Volume:
1.66M
Relative Volume:
0.35
Market Cap:
$4.72B
Revenue:
$330.24M
Net Income/Loss:
$34.79M
P/E Ratio:
-99.75
EPS:
-0.2
Net Cash Flow:
$66.12M
1W Performance:
-8.61%
1M Performance:
+4.40%
6M Performance:
+97.72%
1Y Performance:
+414.18%
1-Day Range:
$19.60
$20.00
1-Week Range:
$18.40
$21.78
52-Week Range:
$3.60
$23.64
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
19.95 | 4.72B | 330.24M | 34.79M | 66.12M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.98 | 119.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.26 | 82.89B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.96 | 37.37B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 32.85B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.70 | 27.50B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Walleye Capital LLC Acquires 25,442 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Verition Fund Management LLC Raises Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Miura Global Management LLC Reduces Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - Zacks Investment Research
ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 6.3% in November - MarketBeat
PDT Partners LLC Invests $1.28 Million in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Charles Schwab Investment Management Inc. Purchases 249,412 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
BNP Paribas Financial Markets Buys 85,250 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 3.4%Time to Sell? - MarketBeat
Citigroup Inc. Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
FORA Capital LLC Buys Shares of 41,547 ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Public Sector Pension Investment Board Takes $9.89 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Has $13.17 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Bank of Montreal Can Has $40.44 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable - MSN
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - MSN
(ADMA) Proactive Strategies - Stock Traders Daily
Intech Investment Management LLC Buys Shares of 62,120 ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Mutual of America Capital Management LLC Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36% - Simply Wall St
ADMA Biologics, Inc. Announces Executive Changes - Marketscreener.com
Advantage Alpha Capital Partners LP Has $1.75 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Penserra Capital Management LLC Invests $2.35 Million in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Algert Global LLC - MarketBeat
Thrivent Financial for Lutherans Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Jennison Associates LLC Makes New $690,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade Sells 15,000 Shares - MarketBeat
Adma Biologics CEO Adam Grossman sells $1.03 million in stock By Investing.com - Investing.com Australia
Adma Biologics CEO Adam Grossman sells $1.03 million in stock - Investing.com India
Adma Biologics CFO Brad Tade sells $317,250 in stock By Investing.com - Investing.com Nigeria
Adma Biologics CFO Brad Tade sells $317,250 in stock - Investing.com India
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fra - GuruFocus.com
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now? - MSN
Segall Bryant & Hamill LLC Trims Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 202,917 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics announces board changes and new audit chair - Investing.com
ADMA Biologics drops as auditor resigns - MSN
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run? - MSN
New Millennium Group LLC Acquires New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
First Turn Management LLC Acquires New Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High? - Yahoo Finance
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Oppenheimer & Co. Inc. - MarketBeat
GSA Capital Partners LLP Sells 109,045 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Zacks Investment Research
Statutory Profit Doesn't Reflect How Good ADMA Biologics' (NASDAQ:ADMA) Earnings Are - Yahoo Finance
Entropy Technologies LP Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
State of New Jersey Common Pension Fund D Has $2.27 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Janney Montgomery Scott LLC Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
3.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):